サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794496

エムポックス・セラピューティクスの世界市場

Mpox Therapeutics

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
エムポックス・セラピューティクスの世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

エムポックス・セラピューティクスの世界市場は2030年までに1億3,270万米ドルに達する見込み

2024年に9,000万米ドルと推定されるエムポックス・セラピューティクスの世界市場は、2030年には1億3,270万米ドルに達し、分析期間2024-2030年のCAGRは6.7%で成長すると予測されます。本レポートで分析したセグメントの1つである天然痘ワクチンは、CAGR 5.4%を記録し、分析期間終了時には7,550万米ドルに達すると予測されます。抗ウイルス剤セグメントの成長率は、分析期間中CAGR 9.0%と推定されます。

米国市場は2,450万米ドルと推定、中国はCAGR 10.3％で成長予測

米国のエムポックス・セラピューティクス市場は、2024年には2,450万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 10.3%で推移し、2030年には予測市場規模2,720万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4％と6.4％と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界のエムポックス・セラピューティクス市場- 主要動向と促進要因のまとめ

なぜ抗ウイルス治療はMpox治療の中心なのか？

抗ウイルス治療は、重症の肺炎罹患者を管理し、合併症を抑える上で極めて重要です。これらの治療は、感染が確認された後、ウイルスの複製を抑えるのに役立ちます。現在利用可能な選択肢には、もともと関連ウイルス用に開発された抗ウイルス薬が含まれています。効果的な治療薬を利用することで、臨床医は免疫不全患者、妊娠中の患者、小児などのハイリスク患者を治療することができます。抗ウイルス療法による早期介入は、患者の転帰を改善し、重症化のリスクを軽減します。

ヘルスケアプロバイダーは、臨床的重症度に基づいて抗ウイルス薬の投与開始と投与量を決定するプロトコルに依存しています。点滴または経口レジメンは、患者の状態や薬剤の入手可能性に応じて選択されます。治療には、副作用のモニタリングや、腎臓や肝臓の機能に応じて治療を調整することも必要です。資源が限られた環境では、抗ウイルス薬の備蓄へのタイムリーなアクセスと明確な治療ガイドラインが、効果的な患者管理には不可欠です。

どのような新しい治療法が登場し、研究されているのでしょうか？

MPOXの罹患率が上昇し、公衆衛生への関心が高まっているため、新規治療法の調査が活発化しています。ウイルスの複製機構を標的とする実験的な薬剤は、様々な臨床開発段階にあります。いくつかの候補薬はより広い抗ウイルス活性を有しています。また、mpox専用に設計されたものもあります。また、ウイルスの中和を目的としたモノクローナル抗体の評価も行われています。これらの治療法は、受動免疫を提供し、重症例や難治性症例をサポートする可能性があります。

臨床試験は、多様な患者群における安全性、投与量、有効性の評価に重点を置いています。特に、小児、高齢者、免疫抑制者などの脆弱な集団における薬剤の影響を理解することに注意が払われています。薬剤開発者はまた、治療効果を高めるために抗ウイルス薬と免疫調節薬を組み合わせた併用療法を模索しています。規制当局は、正式な承認が進む間、より幅広いアクセスを可能にするため、いくつかの治療に対して緊急使用許可を与え始めています。

アクセスと流通はどのように進化しているのか？

エムポックス・セラピューティクスは、公衆衛生ルート、緊急備蓄、国際援助プログラムを通じて配布されています。政府機関、非政府組織、製造業者間のパートナーシップにより、低資源地域における医薬品の配分が促進されています。治療プログラムには、対象となる患者を特定し、治療レジメンを管理し、有害事象を監視するための臨床医に対するトレーニングが含まれることが多いです。このような協調的なアプローチにより、アウトブレイク地帯における公平な治療アクセスが確保されています。

製薬会社はまた、需要の増加に対応するため、生産能力を拡大し、サプライチェーンを再構築しています。必要に応じて生産量を迅速に調整できる柔軟な製造プロセスを模索しています。流通システムには現在、温度管理された輸送、リアルタイムの追跡、遠隔地にも効率的に届く地域ハブなどがあります。このようなロジスティクスの強化は、在庫切れを回避し、流行のピーク時に治療を確実に利用できるようにするために不可欠です。

エムポックス・セラピューティクス市場の成長はいくつかの要因によって牽引される...

エムポックス・セラピューティクス市場の成長はいくつかの要因によって牽引されています。世界の天然痘患者の増加により、効果的な治療に対する需要が高まっています。新規抗ウイルス剤の緊急認可と承認が市場拡大を後押し。脆弱な集団における安全性と有効性をターゲットとした臨床試験への投資により、治療の選択肢が広がります。製造能力のスケールアップと柔軟なサプライチェーンにより、多様な環境でのアクセスが改善されます。国際援助プログラムの拡大により、低資源地域での流通が可能になります。併用療法とモノクローナル抗体への注目の高まりは、治療ポートフォリオの幅を広げ、将来のイノベーションをサポートします。

セグメント

治療（天然痘ワクチン、抗ウイルス剤、ワクシニア免疫グロブリン）;エンドユース（病院エンドユース、専門クリニックエンドユース、外来手術センターエンドユース、その他エンドユース）

調査対象企業の例

  • Aegis Sciences Corporation
  • Bavarian Nordic A/S
  • Baxter International Inc.
  • BioNTech SE
  • Chimerix Inc.
  • CIDIC Company Limited
  • Emergent BioSolutions Inc.
  • Emcure Pharmaceuticals Ltd.
  • Gilead Sciences Inc.
  • Hetero Drugs Limited
  • Mylan N.V.（Viatris）
  • Moderna Inc.
  • Olon S.p.A.
  • Piramal Enterprises Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • SIGA Technologies Inc.
  • SymBio Pharmaceuticals Ltd.
  • Teva Pharmaceutical Ltd.
  • Tonix Pharmaceuticals

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37449

Global Mpox Therapeutics Market to Reach US$132.7 Million by 2030

The global market for Mpox Therapeutics estimated at US$90.0 Million in the year 2024, is expected to reach US$132.7 Million by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Smallpox Vaccine, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$75.5 Million by the end of the analysis period. Growth in the Antivirals segment is estimated at 9.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.5 Million While China is Forecast to Grow at 10.3% CAGR

The Mpox Therapeutics market in the U.S. is estimated at US$24.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$27.2 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Mpox Therapeutics Market - Key Trends & Drivers Summarized

Why Are Antiviral Treatments Central in Mpox Care?

Antiviral treatments are crucial in managing severe mpox cases and limiting complications. These treatments help reduce viral replication once infection is confirmed. Currently available options include antiviral drugs originally developed for related viruses. Access to effective therapeutics enables clinicians to treat high-risk patients, such as immunocompromised individuals, pregnant persons, and children. Early intervention with antiviral therapy improves patient outcomes and reduces the risk of severe disease progression.

Healthcare providers rely on protocols that guide initiation and dosing of antivirals based on clinical severity. Intravenous or oral regimens are selected according to patient condition and drug availability. Treatment also involves monitoring for side effects and adjusting therapy in response to kidney or liver function. In resource-limited settings, timely access to antiviral stockpiles and clear treatment guidelines remain critical for effective patient management.

What New Treatments Are Emerging or Under Study?

Research into novel therapies has intensified due to rising mpox incidence and growing public health interest. Experimental drugs targeting viral replication mechanisms are in various stages of clinical development. Some candidates offer broader antiviral activity. Others are designed specifically for mpox. Research efforts also include evaluating monoclonal antibodies aimed at neutralizing the virus. These treatments may offer passive immunity and support for severe or refractory cases.

Clinical trials focus on assessing safety, dosing, and efficacy across diverse patient groups. Special attention is given to understanding drug impacts in vulnerable populations such as children, elderly people, and immunosuppressed individuals. Drug developers are also exploring combination therapies that pair antivirals with immune modulators to enhance outcomes. Regulatory agencies have begun granting emergency use authorizations for some treatments, enabling broader access while formal approvals progress.

How Are Access and Distribution Evolving?

Mpox therapeutics are being distributed through public health channels, emergency stockpiles, and international aid programs. Partnerships between government agencies, non-governmental organizations, and manufacturers facilitate medicine allocation in low-resource regions. Programs often include training for clinicians to identify eligible patients, manage treatment regimens, and monitor for adverse events. This coordinated approach helps ensure equitable treatment access in outbreak zones.

Pharmaceutical companies are also scaling production capacities and restructuring supply chains to meet increasing demand. They are exploring flexible manufacturing processes that can quickly adapt volumes as needed. Distribution systems now include temperature-controlled transport, real-time tracking, and regional hubs to reach remote areas efficiently. Such logistics enhancements are vital to avoid stockouts and ensure treatment availability during epidemic peaks.

Growth in the Mpox Therapeutics Market Is Driven by Several Factors…

Growth in the mpox therapeutics market is driven by several factors. Rising global mpox cases have increased demand for effective treatments. Emergency authorizations and approvals of new antiviral agents support market expansion. Investment in clinical trials targeting safety and efficacy in vulnerable populations advances therapeutic options. Scale-up of manufacturing capacity and flexible supply chains improves access in diverse settings. Expansion of international aid programs enables distribution in low-resource regions. Growing focus on combination therapies and monoclonal antibodies broadens treatment portfolios and supports future innovation.

SCOPE OF STUDY:

The report analyzes the Mpox Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Aegis Sciences Corporation
  • Bavarian Nordic A/S
  • Baxter International Inc.
  • BioNTech SE
  • Chimerix Inc.
  • CIDIC Company Limited
  • Emergent BioSolutions Inc.
  • Emcure Pharmaceuticals Ltd.
  • Gilead Sciences Inc.
  • Hetero Drugs Limited
  • Mylan N.V. (Viatris)
  • Moderna Inc.
  • Olon S.p.A.
  • Piramal Enterprises Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • SIGA Technologies Inc.
  • SymBio Pharmaceuticals Ltd.
  • Teva Pharmaceutical Ltd.
  • Tonix Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mpox Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Case Burden in Urban and Non-Endemic Regions Drives Demand for Targeted Mpox Treatments
    • Emergency Use Authorization Pathways Spur Accelerated Development of Antiviral Therapies
    • Expansion of Zoonotic Virus Research Throws Spotlight on Broader-Spectrum Antiviral Agents
    • Government Funding and Global Health Partnerships Propel Clinical Trials for Investigational Drugs
    • Increased Use of Tecovirimat and Cidofovir Strengthens Short-Term Market for Repurposed Therapies
    • Vaccine-Linked Immunotherapies Generate Adjacent Market Demand for Prophylactic-Therapeutic Combos
    • Outbreak Management Strategies Support Parallel Growth in Therapeutics Alongside Diagnostics
    • Cross-Application of Smallpox Therapeutics in Mpox Management Sustains Off-Label Prescriptions
    • Focus on Reducing Hospitalization and Complication Rates Enhances Demand for Fast-Acting Treatments
    • Public Health Policies Supporting Post-Exposure Treatment Create Stable Demand for Rapid-Response Drugs
    • Expansion of National Stockpiles and Strategic Reserves Drives Procurement of Antiviral Therapeutics
    • Rising Demand for Oral and Injectable Formulations Supports Diverse Product Delivery Options
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mpox Therapeutics Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mpox Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Smallpox Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Smallpox Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Smallpox Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccinia Immune Globulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccinia Immune Globulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vaccinia Immune Globulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Mpox Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Mpox Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Mpox Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Mpox Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION